News

The grant will enable Melior to test the usage of a drug currently used in other disease areas for its effects in preclinical models of Parkinson’s disease. MJFF

The funding has been received by The University of Texas Medical Branch (UTMB) in Galveston, which is collaborating with Inviragen to develop the vaccine. Inviragen and UTMB had

The company has posted a net income of $1.77m for the second quarter of 2011, compared to $6.32m for the same period in 2010. Lotus’ income from operations

The drug screen study was designed to assess the anti-cancer activity of the selected compounds using a standard cell proliferation assay procedure, against nine human cancer cell lines.

GLP-1 peptide analogs are suitable for all routes of administration including the non-invasive oral or metered nasal spray delivery routes or injection. Aegis’ patented drug delivery and drug

Adnectins are designed by using BMS‘ proprietary PROfusion technology to either block or stimulate the action of specific targets across a range of therapeutic areas. Under the agreement,

The active ingredient in BSCT topical treatment is a polyclonal antibody directed towards Biosceptre’s novel proprietary cancer target, nf-P2X7. Biosceptre expects to start clinical studies for BSCT at

XF-73, a novel dicationic porphyrin, is under development for the prevention of post-surgical Staphylococcal infections. The Phase 1 trial aims to evaluate the safety, tolerability and preliminary anti-Staphylococcal

Intercell has posted a net loss of EUR1.61m for the second quarter of 2011, compared to EUR8.35m for the same period in 2010. The company’s operating loss was